LAVA Therapeutics NV
LVTX
Market Cap$72.56M
Close$
$-2.47
193.3% downside
Current Fair Value
193.3% downsideOvervalued by 193.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $72.56 Million |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $0.0 |
| Beta | 1.69 |
| Outstanding Shares | 26,289,087 |
| Avg 30 Day Volume | 91,728 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 0.0 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
ESG Score
No data
About LAVA Therapeutics NV
LAVA Therapeutics N.V. is a biotechnology company developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its proprietary platform. The...